These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33029052)

  • 21. Recurrence of primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation in Japan.
    Yamagiwa S; Ichida T
    Hepatol Res; 2007 Oct; 37 Suppl 3():S449-54. PubMed ID: 17931201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of ulcerative colitis on liver-related outcomes of children with primary sclerosing cholangitis.
    Sathiaseelan M; Bolia R; Barallon R; Alex G; Hardikar W; Rajanayagam J
    J Paediatr Child Health; 2022 Jul; 58(7):1221-1227. PubMed ID: 35373867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.
    Trivedi PJ; Scalera I; Slaney E; Laing RW; Gunson B; Hirschfield GM; Schlegel A; Ferguson J; Muiesan P
    J Hepatol; 2017 Nov; 67(5):957-965. PubMed ID: 28690174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining long-term outcomes with living donor liver transplantation in North America.
    Olthoff KM; Smith AR; Abecassis M; Baker T; Emond JC; Berg CL; Beil CA; Burton JR; Fisher RA; Freise CE; Gillespie BW; Grant DR; Humar A; Kam I; Merion RM; Pomfret EA; Samstein B; Shaked A
    Ann Surg; 2015 Sep; 262(3):465-75; discussion 473-5. PubMed ID: 26258315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients with benign liver diseases undergoing living donor versus deceased donor liver transplantation.
    Li C; Mi K; Wen Tf; Yan Ln; Li B; Yang Jy; Xu Mq; Wang Wt; Wei Yg
    PLoS One; 2011; 6(11):e27366. PubMed ID: 22087299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histological recurrence of autoimmune liver diseases after living-donor liver transplantation.
    Haga H; Miyagawa-Hayashino A; Taira K; Morioka D; Egawa H; Takada Y; Manabe T; Uemoto S
    Hepatol Res; 2007 Oct; 37 Suppl 3():S463-9. PubMed ID: 17931204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes after ABO-incompatible liver transplantation: A systematic review and meta-analysis.
    Gan K; Li Z; Bao S; Fang Y; Wang T; Jin L; Ma M; Deng L; Peng Y; Li N; Zeng Z; Huang H
    Transpl Immunol; 2021 Dec; 69():101476. PubMed ID: 34601097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience.
    Egawa H; Taira K; Teramukai S; Haga H; Ueda Y; Yonezawa A; Masuda S; Tsuji H; Ashihara E; Takada Y; Uemoto S
    Dig Dis Sci; 2009 Jun; 54(6):1347-54. PubMed ID: 19267192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis.
    Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Hay JE; Charlton MR; Poterucha JJ; Rosen CB; Gores GJ; LaRusso NF; Krom RA
    Hepatology; 1999 Nov; 30(5):1121-7. PubMed ID: 10534330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation.
    Cholongitas E; Shusang V; Papatheodoridis GV; Marelli L; Manousou P; Rolando N; Patch D; Rolles K; Davidson B; Burroughs AK
    Liver Transpl; 2008 Feb; 14(2):138-43. PubMed ID: 18236447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience in Liver Transplantation Due to Primary Sclerosing Cholangitis: A Single Center Experience.
    Emek E; Serin A; Sahin T; Yazici P; Yuzer Y; Tokat Y; Bozkurt B
    Transplant Proc; 2019 Sep; 51(7):2439-2441. PubMed ID: 31405746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy.
    Treeprasertsuk S; Björnsson E; Sinakos E; Weeding E; Lindor KD
    World J Gastrointest Pharmacol Ther; 2013 Aug; 4(3):61-8. PubMed ID: 23919218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.
    Haruki K; Shiba H; Shimada J; Okui N; Iida T; Yanaga K
    Clin J Gastroenterol; 2017 Feb; 10(1):47-51. PubMed ID: 27796825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis.
    Cazzagon N; El Mouhadi S; Vanderbecq Q; Ferreira C; Finnegan S; Lemoinne S; Corpechot C; Chazouillères O; Arrivé L
    JHEP Rep; 2022 Nov; 4(11):100577. PubMed ID: 36277957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary non-resectable liver tumors: A single-center living-donor and deceased-donor liver transplantation case series.
    Lerut J; Iesari S; Vandeplas G; Fabbrizio T; Ackenine K; Núñez MEI; Komuta M; Coubeau L; Ciccarelli O; Bonaccorsi-Riani E
    Hepatobiliary Pancreat Dis Int; 2019 Oct; 18(5):412-422. PubMed ID: 31521538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver transplantation for primary sclerosing cholangitis.
    Solano E; Khakhar A; Bloch M; Quan D; McAlister V; Ghent C; Wall W; Marotta P
    Transplant Proc; 2003 Nov; 35(7):2431-4. PubMed ID: 14611979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis.
    Martin EF; Levy C
    Semin Liver Dis; 2017 Nov; 37(4):305-313. PubMed ID: 29272893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.
    Wan P; Zhang JJ; Li QG; Xu N; Zhang M; Chen XS; Han LZ; Xia Q
    World J Gastroenterol; 2014 Apr; 20(15):4393-400. PubMed ID: 24764678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-Degree Living-Related Donor Liver Transplantation in Autoimmune Liver Diseases.
    Aravinthan AD; Doyle AC; Issachar A; Dib M; Peretz D; Cattral MS; Ghanekar A; McGilvray ID; Selzner M; Greig PD; Grant DR; Selzner N; Lilly LB; Renner EL
    Am J Transplant; 2016 Dec; 16(12):3512-3521. PubMed ID: 27088432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.